TherapeuticsMD (TXMD) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD Announces Second Quarter 2015 Financial Results
August 6, 2015 4:05 PM EDTCompleted Enrollment of 700 Patients in Phase 3 Rejoice Trial; Topline Data Anticipated in Fourth Quarter of 2015 Patient Recruitment for Phase 3 Replenish Trial Advancing; Enrollment Completion Expected during Second Half of 2015 Management to Host Conference call Today at 4:30 p.m. EDT
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its second quarter financial results for the period ended June 30, 2015.
Second Quarter and Recent Developments
... More